

Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Anna K. Abram		
2. Your Title: Deputy Commissioner for Policy, Planning, Legislation, and Analysis		
3. The Entity(ies) You are Representing: U.S. Food and Drug Administration		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No
	X	
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature: _____ Date: 6/4/18

INSTRUCTIONS FOR COMPLETING THE TRUTH-IN-TESTIMONY DISCLOSURE FORM

In General. The attached form is intended to assist witnesses appearing before the Committee on Energy and Commerce in complying with Rule XI, clause 2(g)(5) of the Rules of the House of Representatives, which provides:

(B) In the case of a witness appearing in a nongovernmental capacity, a written statement of proposed testimony shall include a curriculum vitae and a disclosure of any Federal grants or contracts, or contracts or payments originating with a foreign government, received during the current calendar year or either of the two previous calendar years by the witness or by an entity represented by the witness and related to the subject matter of the hearing. (C) The disclosure referred to in subdivision (B) shall include (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government. (D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form not later than one day after the witness appears.

Please complete the form in accordance with these directions.

1. ***Name, Title, Entity(ies) (Items 1-3 on the form).*** Please provide the name and title of the witness and the entity(ies) on whose behalf the witness is testifying.
2. ***Governmental Entity (Item 4).*** Please check the box indicating whether or not the witness is testifying on behalf of a government entity, such as a Federal department or agency, or a State or local department, agency, or jurisdiction. Trade or professional associations of public officials are not considered to be governmental organizations.

Grants and Contracts (Item 5). Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. For each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing, please include the amount and source of each. For each payment or contract originating with a foreign government related to the subject matter of the hearing, please include the amount and country of origin of each. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.

3. ***Curriculum Vitae (Item 6).*** Please attach your CV to your completed disclosure form.
4. ***Submission.*** Please sign and date the form in the appropriate place. Please submit this form with your written testimony. Please note that under the Committee's rules, copies of a written statement of your proposed testimony must be submitted before the commencement of the hearing. To the greatest extent practicable, please also provide a copy in electronic format according to the Electronic Format Guidelines that accompany these instructions.

As Deputy Commissioner for Policy, Planning, Legislation and Analysis, Anna Abram plays a critical role in overseeing the development and implementation of key policy initiatives and provides strategic policy direction to advance FDA's mission and vision of protecting and promoting public health.

Ms. Abram is a respected FDA policy thought leader with more than fourteen years of health care policy experience, including more than a decade of working on health care policy in the United States Senate. She served as the long-time Health Policy Director and Senior Advisor to Senator Richard Burr at the Senate Health, Education, Labor and Pensions (HELP) Committee. In this role, she was actively involved in a range of health care issues under both the Senate HELP and Finance Committees. Her tenure at the Senate HELP Committee was particularly distinguished by her contributions to advancing bipartisan FDA and medical and public health preparedness and response legislation, including securing multiple patient-centered drug and device provisions in the Food and Drug Administration Safety and Innovation Act and 21st Century Cures laws.

Over the years, Ms. Abram has played key roles in advancing legislation to support innovation on behalf of patients and strengthen our nation's public health. She spearheaded the bipartisan negotiation and enactment of the most significant security enhancements to our nation's pharmaceutical supply chain in the past 25 years through the Drug Quality and Security Act. She also was instrumental in strengthening our nation's medical countermeasure work and medical and public health preparedness and response programs through the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013.

Ms. Abram has served as an Associate Director for the Domestic Policy Council at The White House during President George W. Bush's administration. In this role, Ms. Abram coordinated the development and implementation of a range of health care policy issues, including food, drug and public health policy. She coordinated the White House-led, interagency policy process to reauthorize the President's Emergency Plan for AIDS Relief (PEPFAR) in 2008.

Ms. Abram graduated magna cum laude from the University of Pennsylvania.